# Peter Bisgaard > Peter Bisgaard is a Series B investor at NF Life Sciences backing Health Care and Biotechnology. See 19 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [NF Life Sciences](https://shizune.co/investors/profile/nf-life-sciences) - Location: San Francisco, United States - Total investments: 19 - Last investment: Dec 2025 - Lead investor: 42% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/peter-bisgaard-3a244/ - Facebook: http://www.facebook.com/peter.bisgaard.391 Peter Bisgaard is a Series B investor at NF Life Sciences in San Francisco focused on Health Care and Biotechnology. Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2009. He is a member of the Board of Directors of Alder Biopharmaceuticals Inc., Asante Solutions Inc., Ceterix Orthopaedics Inc., HTG Molecular Diagnostics Inc., Nevro Corporation, Otonomy Inc. and Thesan Pharmaceuticals Inc. Previously, he was a board member of several EU and UScompanies.From 2001-2009, Peter was employed with Novo A/S as a partner in Novo Ventures. Prior to joining Novo A/S he was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. At McKinsey, Peter focused on strategy development, mergers, acquisitions and alliances in various industries.Peter is the co-author of 'Growth by Mergers & Acquisitions' published by Børsens Forlag, 2004. Peter obtained an MSc in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 11 | 58% | | Biotechnology | 9 | 47% | | Pharmaceutical | 6 | 32% | | Medical Device | 3 | 16% | | Medical | 2 | 11% | 12 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 5 | 26% | | Series A | 4 | 21% | | Series C | 4 | 21% | | Series D | 3 | 16% | | Series E | 1 | 5% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 10 | 53% | | Iceland | 1 | 5% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Addition Therapeutics | Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M | Series A | Dec 17, 2025 | | | Engrail Therapeutics | Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverageour flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. | $157M | Series B | Mar 19, 2024 | | | Engrail Therapeutics | Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverageour flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. | $32M | Series A | Aug 03, 2021 | | | Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M | Series C | May 04, 2021 | | | Eargo | Eargo is a medical device startup company that produces hearing aids that allow customers to access help for their hearing loss.The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers a rechargeable hearing aids that can be controlled with a smartphone. Its innovativeproduct and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email, or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels. | $81.6M | Series E | Jul 29, 2020 | | | Engrail Therapeutics | Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverageour flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. | $32M | Series A | Jun 18, 2020 | | | OncXerna Therapeutics | OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumormicroenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.The company was founded in 2018 and was formerly known as Oncologie. | $80M | Series B | Jun 10, 2019 | | | Eargo | Eargo is a medical device startup company that produces hearing aids that allow customers to access help for their hearing loss.The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers a rechargeable hearing aids that can be controlled with a smartphone. Its innovativeproduct and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email, or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels. | $52M | Series D | Mar 05, 2019 | | | Oculis | The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $18.1M | Series B | Jan 04, 2019 | | | Eargo | Eargo is a medical device startup company that produces hearing aids that allow customers to access help for their hearing loss.The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers a rechargeable hearing aids that can be controlled with a smartphone. Its innovativeproduct and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. Consumers can purchase online or over the phone and get personalized and convenient consultation and support from licensed hearing professionals via phone, text, email, or video chat. The Eargo solution is offered to consumers at approximately half the cost of competing hearing aids purchased through traditional channels. | $45M | Series C | Oct 19, 2017 | | 10 of 19 investments shown. ## Co-investors - [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 4 deals together - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together - [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 4 deals together - [TPG Biotech](https://shizune.co/investors/profile/tpg-biotech) — VC Fund, 4 deals together - [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 3 deals together - [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together ## About NF Life Sciences VC Fund 1 contacts available at NF Life Sciences. | Name | Title | Profile | | --- | --- | --- | | Peter Bisgaard | Managing Director | https://shizune.co/investors/profile/peter-bisgaard | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Peter Bisgaard invest in? Peter Bisgaard invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Peter Bisgaard last invest? The most recent investment recorded for Peter Bisgaard closed in Dec 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co